Cyclerion Therapeutics (CYCN) Operating Leases (2019 - 2021)

Cyclerion Therapeutics has reported Operating Leases for 3 years, with the latest figure at $38.1 million in Q1 2021.

• On a quarterly basis, Operating Leases fell 19.1% year-over-year to $38.1 million in Q1 2021; TTM through Mar 2021 was $38.1 million, a 19.1% decrease from a year earlier, with the FY2020 full-year figure at $38.9 million, down 44.78% from the prior year.
• Operating Leases was $38.1 million for Q1 2021 at Cyclerion Therapeutics, down from $38.9 million in the prior quarter.
• The five-year high for Operating Leases was $72.4 million in Q2 2019, with the low at $38.1 million in Q1 2021.
• Average Operating Leases over 3 years is $53.1 million, with a median of $46.7 million recorded in 2020.
• The sharpest annual moves came in 2020 and 2021: Operating Leases slumped 44.78% in 2020, then decreased 19.1% in 2021.
• Over 3 years, Operating Leases stood at $70.5 million in 2019, then plunged by 44.78% to $38.9 million in 2020, then retreated by 2.22% to $38.1 million in 2021.
• The last three Operating Leases figures came in at $38.1 million (Q1 2021), $38.9 million (Q4 2020), and $39.8 million (Q3 2020), per Business Quant data.